• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Lupus. Author manuscript; available in PMC Jan 1, 2010.
Published in final edited form as:
PMCID: PMC2707942

Adipocytokines in Systemic Lupus Erythematosus: Relationship to Inflammation, Insulin Resistance and Coronary Atherosclerosis

Cecilia P. Chung, M.D., M.P.H.,1,2 Ashley G. Long, B.S.,1,2 Joseph F. Solus, Ph.D.,3 Young Hee Rho, M.D.,1,2 Annette Oeser, B.S.,1,2 Paolo Raggi, M.D.,4 and C. Michael Stein, M.D.1,2


We tested the hypothesis that concentrations of adipocytokines are altered in SLE and associated with coronary atherosclerosis, insulin resistance and inflammation. Concentrations of resistin, leptin, adiponectin, and visfatin were measured in 109 patients with SLE and in 78 control subjects. Coronary calcification was measured by electron beam computed tomography and insulin resistance was defined by the homeostasis (HOMA) index. Concentrations of adiponectin (28.7+/−17.9 vs. 22.0+/−15.3 µg/mL, p=0.003), leptin (41.1+/−49.9 vs. 19.8+/−24.6 ng/mL, p<0.001) and visfatin (7.5+/−10.5 vs. 4.5+/−2.8 ng/mL, p<0.001) were higher in patients with SLE than controls. These differences remained significant after adjustment for age, race, sex and BMI, (all p-values<0.02). Concentrations of resistin (10.7+/−7.6 vs. 9.1+/−5.1 ng/mL, p=0.41) did not differ in patients and controls. In patients with SLE, leptin was positively associated with BMI (rho=0.80, p<0.001), insulin resistance (rho=0.46, p<0.001), and CRP (rho=0.30, p=0.002), while adiponectin was negatively associated with the same factors (rho= −0.40, p<0.001; rho= −0.38, p<0.001, rho=− 0.22, p=0.02, respectively). None of the adipocytokines were associated with coronary atherosclerosis in SLE. In conclusion, patients with SLE have increased concentrations of adiponectin, leptin and visfatin. Lower concentrations of adiponectin and higher concentrations of leptin are associated with insulin resistance, BMI and CRP in patients with SLE.

Keywords: systemic lupus erythematosus, adipocytokines, atherosclerosis, insulin resistance, inflammation

Adipose tissue has endocrine functions and is the main source of several mediators, termed adipocytokines, which include leptin, resistin, visfatin and adiponectin. These adipocytokines have profound effects on glucose homeostasis, appetite regulation, inflammation and atherosclerosis.1

Leptin, resistin and visfatin have pro-inflammatory and atherogenic effects and are associated with insulin resistance.1, 2 For example, increased concentrations of these three adipocytokines are found in animal models of obesity and in individuals with diabetes,1 and higher concentrations of resistin and leptin are associated with coronary atherosclerosis and coronary events.3, 4 Adiponectin, in contrast, has anti-diabetic, anti-inflammatory and anti-atherogenic effects.1, 5 Lower concentrations of adiponectin are found in patients with diabetes or the metabolic syndrome6 and are associated with the presence and progression of coronary atherosclerosis, independent of traditional cardiovascular risk factors.5

Thus, adipocytokines may provide a mechanistic link between impaired insulin sensitivity, obesity, chronic inflammation, and atherosclerosis. We have reported that patients with systemic lupus erythematosus (SLE) frequently meet the criteria for the metabolic syndrome7, and have accelerated atherosclerosis 8 and a higher prevalence of insulin resistance.7 Little is known about adipocytokines in SLE.9 We therefore examined the hypothesis that concentrations of adipocytokines are altered in SLE and associated with coronary atherosclerosis, insulin resistance and inflammation.


We studied 109 patients with SLE and 78 control subjects who are participating in ongoing clinical investigations into the prevalence and mechanisms of atherosclerosis.7, 8, 1012 Eligible SLE patients included individuals who met the criteria for SLE,13 were over 18 years of age, and had a disease duration of one year or greater. The controls did not meet the criteria for SLE or any other autoimmune disease, and were frequency-matched to the SLE patients for age, sex, and race. Patients were recruited from local rheumatologists in Nashville, Tennessee, USA, from advertisements, and from a Lupus Foundation newsletter. Six subjects with SLE were excluded because of a history of myocardial infarction, angina or stroke. Controls were recruited from advertisements, patients’ acquaintances, and a database maintained by the General Clinical Research Center at Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Subjects were excluded if they had a history of myocardial infarction, angina, or stroke. All subjects provided a written informed consent, and the Institutional Review Board of Vanderbilt University Hospital approved the study.

Patient assessment included a standardized interview, physical examination, laboratory tests, and, in patients, a review of medical records. The use of current and cumulative medications was determined both through chart review and the standardized interview. BMI was calculated using the attained height and weight measurements and waist circumference measured. Blood pressure was determined as the average of two measurements recorded 5 minutes apart after subjects had rested supine for 10 minutes. Subjects were considered to be hypertensive if they were taking anti-hypertensive medications, if their systolic blood pressure was 140 mmHg or higher, or if their diastolic blood pressure was 90 mmHg or higher. After an overnight fast, a blood sample was taken to measure high-density lipoprotein (HDL), total cholesterol, triglycerides, glucose, and insulin. Subjects were considered to be diabetic if they were taking anti-diabetic medications or if their glucose levels were above 126 mg/dl. Low-density lipoprotein (LDL) was calculated. Insulin, leptin, adiponectin, resistin, tumor necrosis factor (TNF) α, interleukin (IL)-6, IL-1a (Linco/Millipore Corp.) and visfatin (Phoenix Pharmaceuticals, Inc.) concentrations were measured using ELISA. In patients with SLE, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were determined. Additionally, for SLE patients, disease activity and damage were measured using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Systemic Lupus International Collaborating Clinics Damage Index (SLICC), respectively.14, 15

To measure coronary atherosclerosis, subjects underwent chest computed tomography imaging with an Imatron C-150 scanner (GE/Imatron, South San Francisco, CA) as described previously.8, 16 Briefly, imaging was performed with a 100-msec scanning time and a single-slice thickness of 3 mm. Forty slices were obtained during a single breath-holding period starting at the aortic arch and proceeding to the level of the diaphragm. All scans were scored, as described by Agatston et al,17 by a single experienced investigator (PR), unaware of the subjects’ clinical status.

Patient and control subjects were classified as having the metabolic syndrome based on the definition set forth by the World Health Organization (WHO). The modified WHO definition requires the presence of insulin resistance, which is defined by any of the following: a homeostasis model assessment (HOMA) index (fasting glucose [mmol/l] * fasting insulin [µU/ml]/22.5) in the top quartile of a non-diabetic population, impaired fasting glucose (≥110mg/dl), or diabetes. In addition to insulin resistance, the WHO definition also requires two of the three following criteria: central obesity (waist >94cm in men and >88cm in women), elevated triglycerides (≥150mg/dl or HDL <35mg/dl in men and <40mg/dl in women, and high blood pressure, defined as ≥140/90 mmHg or the use of hypertensive medications. Based on the Study of Inherited Risk of Coronary Atherosclerosis (SIRCA) data,18 a HOMA index of >2.114 was defined as representative of the top quartile of a non-diabetic population.

Demographic characteristics are presented as mean and standard deviation for continuous variables, or as frequencies and percentages for categorical variables. The differences among cases and controls were determined by Wilcoxon rank sum test or Fisher’s exact test, as appropriate. Adipocytokine concentrations are presented as mean (±SD) and compared in patients with lupus and control subjects by Wilcoxon rank sum tests. To further assess if these differences were independent of age, race, sex, and BMI, linear regressions with adipocytokines (after logarithmic transformation to achieve normal distribution of the residuals) as the dependent variable and disease status (either SLE or control) as the independent variable were modeled. We used Spearman correlations to examine the association between adipocytokines and clinical variables, markers of inflammation and disease characteristics. We used logistic regression to examine the association between the metabolic syndrome and adipocytokines in patients with SLE. Adipocytokines were logarithmically transformed and results are expressed as odds ratios and 95% confidence interval and are further adjusted for CRP and BMI (*except for the model including obesity that was only adjusted for CRP). Logistic regressions were modeled to examine the association between adipocytokines as independent, and coronary artery atherosclerosis as dependent variable. To assess if the association between adipocytokines and coronary atherosclerosis was independent of traditional risk factors, multivariable regressions were modeled using prespecified covariates that are known to be strongly associated with the outcomes of interest (age, race, sex, BMI and Framingham risk score).All analyses used a two-sided significance level of 5 percent and were performed with STATA 9.1.


Patients and control subjects

Patients with lupus and control subjects were of similar age (40.2±11.5 years, and 40.5±12.0 years, respectively, P=0.86) and sex (91.7 and 85.9 percent female, respectively, P=0.24). Seventy-four (68%) patients with lupus and 57 (73%) control subjects were Caucasian. There was a trend toward higher BMI in patients with lupus (29.2±7.5 kg/m2) than in controls (27.0±6.0 kg/m2, P=0.05), and the HOMA index was significantly higher in patients (2.0±1.8 units) than controls (1.5±1.0 units, P=0.04). (Table 1) The mean disease duration of SLE was 8.2±7.3 years, the mean SLEDAI was 4.1±4.0, and the mean SLICC 0.9±1.3. Patients with SLE had a mean ESR of 26.9±27.5 mm/hr and CRP of 6.3±9.1 mg/L.

Table 1
Characteristics of patients and controls

Adipocytokines in SLE patients and controls

As shown in Figure 1, concentrations of adiponectin (28.7+/−17.9 versus 22.0+/−15.3 µg/mL, p=0.003), leptin (41.1+/−49.9 versus 19.8+/−24.6 ng/mL, p<0.001) and visfatin (7.5+/−10.5 versus 4.5+/−2.8 ng/mL, p<0.001) were higher in patients with SLE than controls. These differences between patients with lupus and control subjects remained significant after adjustment for age, race, sex and BMI (all p values < 0.02). There were no significant differences in concentrations of resistin between patients and control subjects (10.7±7.6 and 9.1±5.1 ng/mL respectively, p=0.41).

Figure 1
Concentrations of adipocytokines in patients with SLE and control subjects

Cardiovascular risk factors and adipocytokines

In patients with SLE, adiponectin was significantly negatively correlated with BMI (rho=−0.40) and positively correlated with HDL cholesterol (rho=0.38) (Table 2). Leptin correlated significantly with BMI (rho=0.80), total (rho=0.25) and LDL cholesterol (rho=0.21) and triglycerides (rho=0.22) (Table 2). Visfatin was not significantly associated with any cardiovascular risk factor. Similar results were found in control subjects; adiponectin was significantly negatively correlated with BMI (rho= −0.54) and leptin was significantly positively correlated with it (rho=0.70).

Table 2
Correlation (rho) between adipocytokines and cardiovascular risk factors in patients with SLE

Disease characteristics and adipocytokines in SLE

Among patients with SLE, adiponectin (rho= −0.22) and leptin (rho=0.30) were significantly associated with CRP; resistin (rho=0.23) and leptin (rho=0.20) were associated with ESR. Neither SLEDAI nor SLICC scores were associated with adipocytokine concentrations. (Table 3)

Table 3
Correlations (rho) between adipocytokines and markers of inflammation, disease activity, accrual damage, coronary calcium, insulin resistance and cumulative corticosteroid exposure in patients with SLE

There were 27 (24.8%) patients receiving hormone replacement therapy (HTR), 8 (7.4%) taking statins and 64 (59%) taking corticosteroids. Concentrations of leptin were higher in patients on HTR (50.5±47.8 compared to 38.1±50.5 ng/ml, p=0.03). Adipocytokine concentrations were not related to current use of immunosuppressive therapy (defined as use of cyclophosphamide, azathioprine, mycophenolate, or methotrexate). Concentrations of adiponectin (p=0.85), resistin (p=0.40), leptin (p=0.12) and visfatin (p=0.82) were not significantly different in patients with SLE receiving immunosuppressive therapy and those who were not. There were no other statistically significant differences in adipocytokine concentrations related to current use of HRT, corticosteroids or statins. Furthermore, cumulative exposure to corticosteroids was not significantly correlated with adipocytokine concentrations (Table 3).

Insulin resistance, the metabolic syndrome, and coronary atherosclerosis and adipocytokines in SLE

Lower adiponectin concentrations were significantly associated with the presence of insulin resistance (p=0.001) (Table 4). This association was not significant after adjusting for BMI (p=0.14) and BMI and CRP (p=0.13). Higher concentrations of leptin were also significantly associated with insulin resistance (p<0.001), but were not significant after adjusting for BMI (p=0.77) and BMI and CRP (p=0.47). Neither resistin nor visfatin was associated with insulin resistance. (Table 4) Higher leptin concentrations were associated with the presence of the metabolic syndrome and several individual components of it (obesity, insulin resistance, and hypertension). In contrast, higher adiponectin concentrations were inversely related to the presence of the metabolic syndrome and to the components of obesity, insulin resistance and dyslipidemia.

Table 4
Association between adipocytokines and the metabolic syndrome and its components in SLE

There was no association between coronary calcification and adipocytokines. (Table 5) After statistical adjustment for age and sex the association between resistin and coronary artery calcification was of borderline significance (p=0.06) but not after adjustment for Framingham risk score (p=0.20).

Table 5
Association between adipocytokinesa and presence or absence of coronary calcification in patients with SLE


The main findings of this study are that patients with SLE have increased concentrations of adiponectin, leptin and visfatin, independent of BMI. Lower concentrations of adiponectin and higher concentrations of leptin are associated with insulin resistance. Furthermore, none of the adipocytokines studied was associated with coronary atherosclerosis in SLE.

Mutations resulting in loss of function of the leptin receptor are associated with increased appetite, obesity and hyperglycemia, but leptin concentrations are increased in obesity – a paradox thought to reflect “leptin resistance”.19 Recent information that C-reactive protein binds to leptin, impairs signaling and mediates leptin resistance,20 suggests that leptin resistance may be more likely in the setting of chronic inflammation. Indeed, leptin and CRP concentrations were independently associated in healthy volunteers.21 Leptin also induces CRP expression in vitro 22 and is both pro-inflammatory 21 and atherogenic;23 increased concentrations are associated with insulin resistance and are an independent risk factor for coronary heart disease.4

There is little information about leptin in SLE. Leptin concentrations were higher in patients than in controls, 9, 24 suggesting a relationship between leptin and lupus disease related factors. We found that leptin concentrations were increased in SLE, and as would be expected, leptin was strongly associated with BMI. We also showed, for the first time in SLE, an association between leptin and insulin resistance, the metabolic syndrome, CRP, ESR, LDL cholesterol and triglycerides. Although leptin was strongly associated with obesity in SLE, the difference in leptin concentrations between patients with lupus and controls was independent of age, race, sex and BMI, suggesting that additional factors drive leptin production or alter the relationship between obesity and leptin in lupus.

Visfatin is a recently discovered adipocytokine that binds to the insulin receptor and is thought to be secreted to compensate for insulin resistance.25 It is also pro-inflammatory and associated with unstable atherosclerotic lesions.26 In addition to its potential role in glucose metabolism and atherosclerosis, visfatin has been linked with inflammation and concentrations are increased in patients with rheumatoid arthritis.27 To the best of our knowledge there is no information about visfatin in SLE. Visfatin concentrations were significantly higher in patients with SLE than controls but were not associated with metabolic or inflammatory measures. This is concordant with some recent population studies, including the Framingham Offspring Cohort, that found no relationship between visfatin concentrations and metabolic variables.28 Visfatin, previously known as pre-B-cell colony enhancing factor, activates human leukocytes and stimulates the production of cytokines such as IL-6. 25 Thus, although not associated with the inflammatory mediators and markers we measured, the elevated concentrations of visfatin observed could reflect inflammation in SLE.

Resistin mediates obesity-induced insulin resistance in a mouse model of obesity.29 The administration of anti-resistin antibodies improved blood glucose and insulin action, and rosiglitazone, an antidiabetic drug, decreased resistin concentrations in an animal model.30 In humans, resistin has been associated with obesity, diabetes and inflammation in some studies.3, 31 However, its role in SLE is poorly defined. We did not find a statistically significant difference in resistin concentrations among patients with SLE and control subjects. Consistent with our data, in patients with RA, concentrations of resistin were not higher than in controls, although there were differences in leptin, adiponectin and visfatin.27 We found a relatively weak association between resistin and ESR but no association with CRP, IL-6, TNF and HOMA. These findings are largely compatible with those of the SIRCA study that found no relationship between resistin and HOMA and only a weak association with CRP and IL-6 (rho=0.10 and 0.16, respectively) in a community-based sample of asymptomatic subjects from the general population.3

Adiponectin is secreted by adipose tissue, but in contrast to leptin, resistin and visfatin, has anti-diabetic, anti-inflammatory and anti-atherogenic effects.1, 5 Adiponectin acts as an insulin sensitizer 1 and decreases the inflammatory response induced by TNF-α.32 Thus, low concentrations of adiponectin are associated with obesity, insulin resistance and dyslipidemia.32, 33 Patients with SLE have higher concentrations of adiponectin than controls,9 and we show that despite this increase, the inverse relationship between adiponectin and BMI, HOMA, metabolic syndrome, systolic blood pressure and dyslipidemia persist in SLE. Thus, the increase in adiponectin concentrations in SLE might reflect a partial compensatory response to these metabolic perturbations.

In addition to their role in mediating the metabolic and inflammatory changes associated with obesity, adipocytokines may play a role in atherogenesis. Leptin concentrations are associated with risk of coronary events,4 and in type 2 diabetics, with coronary calcification.34 Similarly, resistin concentrations are associated with coronary calcification 3 and carotid intima-media thickness.35 Conversely, low concentrations of adiponectin are associated with increased risk of myocardial infarction and progression of coronary calcification.5, 36 In our patients with SLE, although concentrations of leptin were elevated, and in this same cohort of subjects atherosclerosis was accelerated,8 we found no relationship between concentrations of adipocytokines and coronary calcification. There are several possible explanations. First, other unidentified risk factors may drive atherosclerosis in SLE and obscure the effect of adipocytokines. Second, the increased concentrations of adiponectin could offset the adverse cardiovascular effects of increased concentrations of leptin. This appears to be unlikely since we also examined the leptin:adiponectin ratio - a parameter that may provide a better measure of atherogenic risk than either adipocytokine alone 37 and found no relationship to coronary calcification.

Our data suggest that adipocytokines are associated with inflammatory markers but not with disease activity, as measured with the SLEDAI score. Although perhaps counterintuitive, the correlation between the SLEDAI score and laboratory markers of inflammation is relatively weak, for example in our population the correlation between SLEDAI and ESR and CRP (r=0.21 for both) explained only approximately 4% of the variance.

This study has some limitations. First, our observations are based on a cross-sectional rather than a longitudinal analysis, and thus the analysis only includes a single measurement of adipocytokines. Multiple measurements of adipocytokines over time are likely to provide additional information. Second, this is a population with relatively low disease activity, and therefore our findings may not be applicable to patients with very active disease.

In conclusion, patients with SLE have higher concentrations of adiponectin, leptin and resistin. Leptin (positively) and adiponectin (negatively) were associated with BMI, insulin resistance, CRP and the metabolic syndrome. Coronary calcification was not related to adipocytokines. Adipocytokines may provide a link between insulin resistance and inflammation in SLE.


This study was supported by grants (HL65082, GM5M01-RR00095 and 1UL1RR024975) from the National Institutes of Health.

Reference List

1. Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol. 2006;57(4):505–528. [PubMed]
2. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev. 2007;18(3–4):313–325. [PubMed]
3. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111(7):932–939. [PubMed]
4. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS) Circulation. 2001;104(25):3052–3056. [PubMed]
5. Maahs DM, Ogden LG, Kinney L, et al. Low Plasma Adiponectin Levels Predict Progression of Coronary Artery Calcification. Circulation. 2005;111(6):747–753. [PubMed]
6. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin--a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 2006;8(3):264–280. [PubMed]
7. Chung CP, Avalos I, Oeser A, et al. High Frequency of the Metabolic Syndrome in Patients with Systemic Lupus Erythematosus: Association with Disease Characteristics and Cardiovascular Risk Factors. Ann Rheum Dis. 2007;66(2):208–214. [PMC free article] [PubMed]
8. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Eng J Med. 2003;349(25):2407–2415. [PubMed]
9. Sada KE, Yamasaki Y, Maruyama M, et al. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol. 2006;33(8):1545–1552. [PubMed]
10. Asanuma Y, Chung CP, Oeser A, et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol. 2006;33(3):539–545. [PubMed]
11. Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum. 2005;52(11):3651–3659. [PubMed]
12. Chung CP, Oeser A, Avalos I, Raggi P, Stein CM. Cardiovascular Risk Scores Underestimate the Presence of Subclinical Coronary-Artery Atherosclerosis in Women with Systemic Lupus Erythematosus. Lupus. 2006;15:562–569. [PubMed]
13. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–1277. [PubMed]
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630–640. [PubMed]
15. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363–369. [PubMed]
16. Chung CP, Oeser A, Raggi P, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: Relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 2005;52(10):3045–3053. [PubMed]
17. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Vaimonte M, Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827–832. [PubMed]
18. Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation. 2004;110(7):803–809. [PubMed]
19. Ahima RS, Flier JS. Leptin. Annual Review of Physiology. 2000;62(1):413–437. [PubMed]
20. Chen K, Li F, Li J, et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med. 2006;12(4):425–432. [PubMed]
21. Shamsuzzaman AS, Winnicki M, Wolk R, et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation. 2004;109(18):2181–2185. [PubMed]
22. Singh P, Hoffmann M, Wolk R, Shamsuzzaman AS, Somers VK. Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27(9):e302–e307. [PubMed]
23. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006;189(1):47–60. [PubMed]
24. Garcia-Gonzalez A, Gonzalez-Lopez L, Valera-Gonzalez IC, et al. Serum leptin levels in women with systemic lupus erythematosus. Rheumatol Int. 2002;22(4):138–141. [PubMed]
25. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties. J Immunol. 2007;178(3):1748–1758. [PubMed]
26. Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007;115(8):972–980. [PubMed]
27. Otero M, Lago R, Gomez R, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(9):1198–1201. [PMC free article] [PubMed]
28. Ingelsson E, Larson MG, Fox CS, et al. Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care. 2007;30(5):1278–1280. [PubMed]
29. Shuldiner AR, Yang R, Gong DW. Resistin, Obesity, and Insulin Resistance -- The Emerging Role of the Adipocyte as an Endocrine Organ. N Engl J Med. 2001;345(18):1345–1346. [PubMed]
30. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307–312. [PubMed]
31. Kunnari A, Ukkola O, Paivansalo M, Kesaniemi YA. High Plasma Resistin Level Is Associated with Enhanced Highly Sensitive C-Reactive Protein and Leukocytes. J Clin Endocrinol Metab. 2006;91(7):2755–2760. [PubMed]
32. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24(1):29–33. [PubMed]
33. von EM, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem. 2006;52(5):853–859. [PubMed]
34. Reilly MP, Iqbal N, Schutta M, et al. Plasma Leptin Levels Are Associated with Coronary Atherosclerosis in Type 2 Diabetes. J Clin Endocrinol Metab. 2004;89(8):3872–3878. [PubMed]
35. Shin HJ, Park S, Yoon SJ, et al. Association between serum resistin and carotid intima media thickness in hypertension patients. Int J Cardiol. 2007 [PubMed]
36. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma Adiponectin Levels and Risk of Myocardial Infarction in Men. JAMA. 2004;291(14):1730–1737. [PubMed]
37. Satoh N, Naruse M, Usui T, et al. Leptin-to-Adiponectin Ratio as a Potential Atherogenic Index in Obese Type 2 Diabetic Patients. Diabetes Care. 2004;27(10):2488–2490. [PubMed]
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...